Novel Permissive Role of Epidermal Growth Factor in Transforming Growth Factor β (TGF-β) Signaling and Growth Suppression

Song, Kyung; Krebs, Tracy L.; Danielpour, David

doi:10.1074/jbc.m511781200

Cited by 24 publications

(23 citation statements)

References 59 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies showed that in most cells EGF is growth stimulatory and anti-apoptotic; however, a number of tumor cell lines have been shown to be killed by this peptide through unknown mechanisms [31][32][33]. Consistent with these studies, our results showed that EGF has a negative role to regulate the Mac-2BP expression, although it couldn' t detect the apoptotic process.…”

Section: G L 2 S Ir N a S T A T 3 S Ir N A H T E R T 236supporting

confidence: 82%

Role of STAT3 as a Negative Regulator in Mac2- Binding Protein Expression

et al. 2008

View full text Add to dashboard Cite

Section: G L 2 S Ir N a S T A T 3 S Ir N A H T E R T 236supporting

confidence: 82%

Role of STAT3 as a Negative Regulator in Mac2- Binding Protein Expression

et al. 2008

View full text Add to dashboard Cite

“…Recent studies reported EGF can inhibit or stimulate Fas-induced apoptosis [14,20,25], and the EGF receptor (EGFR) is frequently upregulated in response to chemotherapy [11,42]. EGF can also modulate TGFb and/ or Fas/FasL expression and activity [14,40,45]. Hypothetically, EGF could interact with the FADD pathway by modulating Fas ligand activity.…”

Section: Introductionmentioning

confidence: 99%

Fas Death Pathway in Sarcomas Correlates with Epidermal Growth Factor Transcription

Joyner

Aboulafia

Damron

et al. 2008

Clin Orthop Relat Res

View full text Add to dashboard Cite

Modulation of apoptosis may influence sarcoma pathogenesis and/or aggressiveness. The Fas death pathway, mediated by FasL or TGFb, is one of two apoptotic pathways. Recent studies report that EGF can modulate TGFb and/or FasL expression/activity; thus, EGF has the potential to influence activation of the Fas pathway. EGF is not always detectable in mesenchymal tumors; therefore, we hypothesized EGF would define which Fas ligand predominates. We assayed 57 surgically removed human sarcomas for 10 genes involved in the Fas pathway. Skeletal muscle biopsies from eight patients served as controls. Sample transcripts were detected by real-time RT-PCR. We attempted to identify relevant predictor variables. The 57 sarcomas were segregated into two categories defined by EGF mRNA content: (1) 23 tumors with EGF concentrations that approximated muscle EGF transcript levels (high-EGF tumors); and (2) 34 tumors that either lacked EGF mRNA, or whose mRNA levels were very low and frequently undetected by PCR (low-EGF tumors). TGFb1 expression best predicted Fas transcript concentrations in the 34 low-EGF sarcomas, while FasL predicted Fas mRNA levels in the remaining 23 high-EGF sarcomas. The results suggest ligand activity in the Fas death pathway correlates with EGF transcription in sarcomas.

show abstract

“…However, the specific roles of individual AP-1 family members in the development and progression of prostate cancer are still largely unknown. Few reports have shown the effects, if any, of TGF-␤ on AP-1 in prostate cancer (61)(62)(63).…”

mentioning

confidence: 99%